NASDAQ:MBRX Moleculin Biotech Q3 2026 Earnings Date & Estimates $0.28 -0.09 (-24.24%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.93%) As of 10/16/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Moleculin Biotech is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Moleculin Biotech in Q3 2026Moleculin Biotech is expected to post earnings of -$0.4433 per share. In the same quarter a year earlier Moleculin Biotech reported -$0.13 per share. Moleculin Biotech last reported on August 13, 2026, posting -$1.40 per share and beating the -$1.55 consensus estimate. Moleculin Biotech has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.4433Prior-Year EPS-$0.13Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.40 (Beat by +$0.15)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Moleculin Biotech Q3 2026 Earnings FAQ When does Moleculin Biotech report Q3 2026 earnings? Moleculin Biotech (NASDAQ:MBRX) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Moleculin Biotech's Q3 2026 earnings call? Moleculin Biotech's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Moleculin Biotech? Analysts expect Moleculin Biotech to post earnings of -$0.4433 per share for Q3 2026. Moleculin Biotech Earnings HeadlinesMoleculin Biotech Updates Investors With New PresentationOctober 16 at 11:50 AM | tipranks.comMoleculin Biotech To Effect 1-for-20 Reverse Stock SplitOctober 16 at 11:07 AM | rttnews.comBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom. | Brownstone Research (Ad)Moleculin Announces Reverse Stock SplitOctober 16 at 9:20 AM | globenewswire.comMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitOctober 7, 2026 | globenewswire.comMoleculin Biotech Updates Investors With New PresentationOctober 5, 2026 | tipranks.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research programs are based on compounds designed to target biological mechanisms involved in tumor growth, drug resistance and immune-system regulation. The company’s lead program is annamycins, including L-annamycin, an anthracycline designed to retain anticancer activity while reducing some limitations associated with conventional anthracyclines, particularly damage to the heart. Moleculin has studied annamycin in clinical programs for acute myeloid leukemia and soft-tissue sarcoma. Its broader oncology pipeline has included WP1066, a STAT3 pathway inhibitor being investigated for cancers such as glioblastoma, and related compounds targeting oncogenic signaling pathways. Moleculin is headquartered in Houston, Texas, and its development activities have included clinical research in the United States and international locations. Walter Klemp has served as the company’s chairman and chief executive officer. As a clinical-stage biotechnology company, Moleculin’s programs remain subject to clinical, regulatory and commercial development risks.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/12 - 10/16Bank of America Stock Sell-Off Looks Like a Buying OpportunityManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay SolidMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers? Upcoming Earnings America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026)Northrop Grumman (10/20/2026)RTX (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
